Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Attovia Therapeutics, Inc.NASDAQ: ATTO
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA of -$21.56M in Q2 FY2026
Q2 FY2026 EBITDA was -$21.56M.
Context
- EBITDA amounted to 4915.2% of revenue in FY2025.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (66.36M) USD
- Year-over-year change
- -60.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (66.36M) | -60.9% |
| FY2024 | 2024-12-31 | (41.24M) | — |
EBITDA vs competitors
How ATTO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -60.9% is the 7th highest of 10, against a peer median of -31.5%.
- EBITDA amounts to 4915.2% of revenue for ATTO, versus a peer median of 795.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $58.49M USD | +176.6% | — | 25.2% | |
| LTM Mar 2026 | $22.15M USD | +154.8% | — | 41.2% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | -€45.89M EUR | -286.3% | — | — |
| FY2025 | -$54.58M USD | -270.2% | — | 85279.7% | |
| FY2025 | -$66.36M USD | -60.9% | — | 4915.2% | |
| LTM Mar 2026 | -$70.61M USD | -31.5% | — | 843.9% | |
EVMNEvommune, Inc. | LTM Mar 2026 | -$74.62M USD | — | — | 746.2% |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.38M USD | -21.4% | — | — |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | -$161.31M USD | -42.5% | — | — |
| LTM Mar 2026 | -$245.81M USD | -69.1% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$442.87M USD | -9.5% | — | 5986.3% |
| Peer median (excluding ATTO) | — | -31.5% | — | 795.1% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 1.35M |
| Cost of Revenue | 313K | 804K |
| Gross Profit | (313K) | 546K |
| Gross Margin | — | 40.4% |
| Research & Development | 33.86M | 54.15M |
| Selling, General & Admin | 7.38M | 13.55M |
| Operating Expenses | 41.24M | 67.71M |
| Depreciation & Amortization | 313K | 804K |
| EBITDA | (41.24M) | (66.36M) |
| EBITDA Margin | — | -4915.2% |
| Operating Income | (41.55M) | (67.16M) |
| Operating Margin | — | -4974.7% |
| Interest Income | 3.44M | 6.63M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 1.75M | 6.53M |
| Income Before Tax | (39.8M) | (60.63M) |
| Pre-Tax Margin | — | -4490.9% |
| Income Tax Expense | 0 | 0 |
| Net Income | (39.8M) | (60.63M) |
| Net Margin | — | -4490.9% |
| EPS (Basic) | (1.05) | (1.42) |
| EPS (Diluted) | (1.05) | (1.42) |
| Weighted Avg Shares | 43.03M | 43.03M |
| Weighted Avg Shares (Diluted) | 43.03M | 43.03M |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.